Latest Content

New data show illness perception and functional capacity influence each other in older adults with COPD and diabetes after hospital discharge.

In part 2, Rick Couldry, MS/HSPA, provides necessary nuance to the value driving cloud-based medication management to the forefront of health care.

Data show that TyG-WC, an index combining insulin resistance and central adiposity, is the only surrogate marker independently linked to osteoporosis.

Across 3 survey periods spanning 2017 to 2023, researchers assess various institutions’ knowledge of pneumococcal vaccination.

A cohort of Black and white Americans was asked about medical racism, misinformation, COVID-19 vaccine safety, and more.

Policy shifts in Medicare and advancements in automation are creating a massive opportunity for both revenue growth and clinical impact.

This episode provides a detailed breakdown of the CVS Caremark-FTC settlement from July, exploring a shifting landscape of pharmacy benefit management.

A year of ACIP turnover, schedule changes, and lawsuits has fractured US vaccine guidance—and tied pharmacists' scope and billing to a moving target.

The current crisis of staffing shortage is not just a labor shortage but a structural failure in how pharmacies recruit and value their technician workforce.

The expanded approval adds a self-administered autoinjector option and new label language tying LDL-C lowering to reduced cardiovascular risk.

Although DSCSA is often viewed as a regulatory burden, pharmacy leaders illustrate its necessity through harrowing case studies of supply chain failures.

Pharmacy leaders urge regional alliances, scalable clinical services, and data exchange to make pharmacist care reimbursable and routine.

Researchers assess the effects of pharmacist support in enhancing GLP-1 access in a primary care setting.

Rural pharmacist explains how local pharmacies close care gaps in older, rural patients by improving vaccine access, education, and on-time immunizations.

Pharmacists must navigate peptide and GLP-1 compounding legally by understanding 503A vs 503B rules.

The year 2026 has brought a stark paradox to American pharmacy practice, and it’s affecting the most sought-after prescription drugs on the market.

The pharmacy benefits industry is undergoing a massive restructuring, driven by a wave of government action designed to shift focus back to the patient.

The academy's updated influenza guidance arrives days after a White House executive order narrowed the recommended childhood vaccine schedule.

A new pharmacy-based program in rural America is potentially identifying and saving thousands of patients from cardiovascular disease.

As reimbursement rates continue to erode and operating costs climb, independent pharmacy owners are being forced to think like CFOs—not just clinicians.

Researchers explore the role of pharmacists in medication reconciliation and patient counseling.

New intranasal etripamil lets adults self-treat sudden paroxysmal supraventricular tachycardia episodes.

In part 2, McMahan contextualizes the recent FTC-Caremark settlement with some of the industry’s major reform efforts in recent history.

Dispensary of Hope delivers donated medications to uninsured patients, cutting emergency room visits and redefining pharmacy’s role in access.

Pharmacies are expanding vaccine access for flu, COVID, and other shots while debunking safety myths and adding test-to-treat services to improve patient care.

Researchers map the structural components that allow for a more patient-centered approach across pharmacist-led management.

Pharmacist-backed travel kit picks tackle motion sickness, dehydration, and stomach upsets for on-the-go relief.

Researchers aim to better understand the perspectives of providers amid ongoing transformations.

The White House and the American Academy of Pediatrics leave pharmacists navigating 2 competing sets of vaccine guidance for the upcoming season.

This episode provides an introspective look at the people in pharmacy who are the hardest to lead toward a path of success.

A decades-long research effort in mRNA-produced licensed vaccines targets influenza, respiratory syncytial virus, cytomegalovirus, HIV, and cancer.